These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 21692951

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.
    Koskinas J, Zacharakis G, Sidiropoulos J, Elefsiniotis J, Savvas S, Kotsiou S, Kountouras D, Schina M, Kostopoulos P, Archimandritis A.
    J Med Virol; 2009 May; 81(5):848-52. PubMed ID: 19319942
    [Abstract] [Full Text] [Related]

  • 3. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
    Koirala J, Gandotra SD, Rao S, Sangwan G, Mushtaq A, Htwe TH, Adamski A, Blessman D, Khardori NM.
    J Viral Hepat; 2007 Nov; 14(11):782-7. PubMed ID: 17927614
    [Abstract] [Full Text] [Related]

  • 4. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
    Carrión JA, Gonzalez-Colominas E, García-Retortillo M, Cañete N, Cirera I, Coll S, Giménez MD, Márquez C, Martin-Escudero V, Castellví P, Navinés R, Castaño JR, Galeras JA, Salas E, Bory F, Martín-Santos R, Solà R.
    J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents.
    Mac Nicholas R, Norris S.
    Aliment Pharmacol Ther; 2010 May; 31(9):929-37. PubMed ID: 20175767
    [Abstract] [Full Text] [Related]

  • 7. Role of epoetin alfa in maintaining ribavirin dose.
    Afdhal NH.
    Gastroenterol Clin North Am; 2004 Mar; 33(1 Suppl):S25-35. PubMed ID: 15081101
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lenograstim in the treatment of severe neutropenia in patients treated with Peg-IFN and ribavirin: the experience of a single hepatology unit.
    Tarantino L, De Rosa A, Tambaro O, Ripa C, Celiento M, Schiano A.
    Infez Med; 2009 Mar; 17(1):20-3. PubMed ID: 19359820
    [Abstract] [Full Text] [Related]

  • 10. Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice.
    Niederau C, Mauss S, Böker K, Lutz T, Heyne R, Moog G, John C, Witthöft T, Alshuth U, Hüppe D.
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):65-73. PubMed ID: 23751351
    [Abstract] [Full Text] [Related]

  • 11. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
    Nordstrom EM, Keniston A, Baouchi F, Martinez-Camacho A.
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117
    [Abstract] [Full Text] [Related]

  • 12. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin.
    Collantes RS, Younossi ZM.
    J Clin Gastroenterol; 2005 Jan; 39(1 Suppl):S9-13. PubMed ID: 15597026
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
    Pontali E, Angeli E, Cattelan AM, Maida I, Nasta P, Verucchi G, Caputo A, Iannacone C, Puoti M.
    Antivir Ther; 2015 Jan; 20(1):39-48. PubMed ID: 24831457
    [Abstract] [Full Text] [Related]

  • 16. [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection].
    Cheong HR, Woo HY, Heo J, Yoon KT, Kim DU, Kim GH, Kang DH, Song GA, Cho M.
    Korean J Hepatol; 2010 Mar; 16(1):38-48. PubMed ID: 20375641
    [Abstract] [Full Text] [Related]

  • 17. Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C.
    Liu YL, Du XF, Chen XY, Ma LN, Guo DD, Lu JF, Cao ZH, Zhang YH.
    Scand J Infect Dis; 2013 Dec; 45(12):939-43. PubMed ID: 24090457
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.
    Bruno R, Cariti G, Nasta P, Capetti A, Ravasio V, Galli M, Raise E, Palmieri G, Iannacone C, Puoti M.
    Liver Int; 2015 Jan; 35(1):120-9. PubMed ID: 25041136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.